Synergy Pharmaceuticals Inc (SGYP) Shares Bought by Vanguard Group Inc.

Vanguard Group Inc. lifted its position in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) by 5.9% during the 3rd quarter, according to the company in …

Synergy Pharmaceuticals logoVanguard Group Inc. lifted its position in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) by 5.9% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 22,025,593 shares of the biopharmaceutical company’s stock after purchasing an additional 1,224,873 shares during the quarter. Vanguard Group Inc. owned about 8.88% of Synergy Pharmaceuticals worth $37,444,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Bank of America Corp DE boosted its position in Synergy Pharmaceuticals by 272.9% during the second quarter. Bank of America Corp DE now owns 243,363 shares of the biopharmaceutical company’s stock valued at $423,000 after buying an additional 384,085 shares during the period. Chicago Equity Partners LLC lifted its holdings in Synergy Pharmaceuticals by 153.5% in the third quarter. Chicago Equity Partners LLC now owns 472,535 shares of the biopharmaceutical company’s stock worth $803,000 after buying an additional 286,135 shares during the period. Nexthera Capital LP bought a new position in shares of Synergy Pharmaceuticals during the third quarter valued at approximately $1,269,000. Hikari Power Ltd increased its stake in shares of Synergy Pharmaceuticals by 8.7% during the third quarter. Hikari Power Ltd now owns 2,500,000 shares of the biopharmaceutical company’s stock valued at $4,250,000 after purchasing an additional 200,000 shares in the last quarter. Finally, BlackRock Inc. increased its stake in shares of Synergy Pharmaceuticals by 2.2% during the second quarter. BlackRock Inc. now owns 21,732,054 shares of the biopharmaceutical company’s stock valued at $37,815,000 after purchasing an additional 464,195 shares in the last quarter. 37.22% of the stock is currently owned by hedge funds and other institutional investors.

SGYP has been the subject of a number of analyst reports. BTIG Research downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Friday, October 26th. Canaccord Genuity downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, October 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and one has given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $5.33.

Shares of SGYP traded down $0.01 on Tuesday, hitting $0.28. 678,439 shares of the stock traded hands, compared to its average volume of 14,718,365. The company has a market capitalization of $68.93 million, a P/E ratio of -0.28 and a beta of 4.94. Synergy Pharmaceuticals Inc has a one year low of $0.07 and a one year high of $2.26.

COPYRIGHT VIOLATION NOTICE: This article was first posted by Fairfield Current and is the sole property of of Fairfield Current. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.fairfieldcurrent.com/news/2019/02/12/synergy-pharmaceuticals-inc-sgyp-shares-bought-by-vanguard-group-inc.html.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.

Featured Story: SEC Filing

Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

BlackRock Inc. Increases Holdings in Synergy Pharmaceuticals Inc (NASDAQ:SGYP)

BlackRock Inc. lifted its position in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) by 2.6% in the 3rd quarter, according to its most recent Form 13F …

Synergy Pharmaceuticals logoBlackRock Inc. lifted its position in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) by 2.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,300,724 shares of the biopharmaceutical company’s stock after acquiring an additional 568,670 shares during the quarter. BlackRock Inc. owned 8.99% of Synergy Pharmaceuticals worth $37,910,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the stock. Metropolitan Life Insurance Co. NY raised its stake in shares of Synergy Pharmaceuticals by 81.7% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 87,170 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 39,189 shares during the period. Bank of America Corp DE grew its holdings in Synergy Pharmaceuticals by 272.9% in the 2nd quarter. Bank of America Corp DE now owns 243,363 shares of the biopharmaceutical company’s stock valued at $423,000 after buying an additional 384,085 shares in the last quarter. Chicago Equity Partners LLC grew its holdings in Synergy Pharmaceuticals by 153.5% in the 3rd quarter. Chicago Equity Partners LLC now owns 472,535 shares of the biopharmaceutical company’s stock valued at $803,000 after buying an additional 286,135 shares in the last quarter. Schwab Charles Investment Management Inc. grew its holdings in Synergy Pharmaceuticals by 7.2% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 1,312,030 shares of the biopharmaceutical company’s stock valued at $2,283,000 after buying an additional 88,386 shares in the last quarter. Finally, Hikari Power Ltd grew its holdings in Synergy Pharmaceuticals by 8.7% in the 3rd quarter. Hikari Power Ltd now owns 2,500,000 shares of the biopharmaceutical company’s stock valued at $4,250,000 after buying an additional 200,000 shares in the last quarter. Hedge funds and other institutional investors own 38.60% of the company’s stock.

Shares of NASDAQ SGYP opened at $0.33 on Thursday. The stock has a market cap of $74.39 million, a PE ratio of -0.32 and a beta of 3.02. Synergy Pharmaceuticals Inc has a fifty-two week low of $0.07 and a fifty-two week high of $2.80.

Synergy Pharmaceuticals (NASDAQ:SGYP) last released its quarterly earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The business had revenue of $11.11 million during the quarter, compared to the consensus estimate of $15.65 million.

A number of equities analysts have recently weighed in on the company. Canaccord Genuity cut Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 26th. Zacks Investment Research cut Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 10th. Finally, BTIG Research cut Synergy Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Friday, October 26th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has assigned a buy rating to the company. Synergy Pharmaceuticals has a consensus rating of “Hold” and an average price target of $6.50.

ILLEGAL ACTIVITY NOTICE: “BlackRock Inc. Increases Holdings in Synergy Pharmaceuticals Inc (NASDAQ:SGYP)” was first reported by Fairfield Current and is the property of of Fairfield Current. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The correct version of this piece of content can be accessed at https://www.fairfieldcurrent.com/news/2019/01/24/blackrock-inc-has-37-91-million-stake-in-synergy-pharmaceuticals-inc-sgyp.html.

Synergy Pharmaceuticals Profile

Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.

Featured Story: Short Selling

Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

BlackRock Inc. Has $37.91 Million Stake in Synergy Pharmaceuticals Inc (SGYP)

BlackRock Inc. grew its position in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) by 2.6% during the 3rd quarter, according to the company in its …

Synergy Pharmaceuticals logoBlackRock Inc. grew its position in Synergy Pharmaceuticals Inc (NASDAQ:SGYP) by 2.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 22,300,724 shares of the biopharmaceutical company’s stock after acquiring an additional 568,670 shares during the period. BlackRock Inc. owned about 8.99% of Synergy Pharmaceuticals worth $37,910,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Chicago Equity Partners LLC boosted its holdings in shares of Synergy Pharmaceuticals by 153.5% in the third quarter. Chicago Equity Partners LLC now owns 472,535 shares of the biopharmaceutical company’s stock valued at $803,000 after acquiring an additional 286,135 shares in the last quarter. Metropolitan Life Insurance Co. NY boosted its holdings in Synergy Pharmaceuticals by 81.7% during the second quarter. Metropolitan Life Insurance Co. NY now owns 87,170 shares of the biopharmaceutical company’s stock worth $152,000 after buying an additional 39,189 shares in the last quarter. Bank of America Corp DE boosted its holdings in Synergy Pharmaceuticals by 272.9% during the second quarter. Bank of America Corp DE now owns 243,363 shares of the biopharmaceutical company’s stock worth $423,000 after buying an additional 384,085 shares in the last quarter. Hikari Power Ltd boosted its holdings in Synergy Pharmaceuticals by 8.7% during the third quarter. Hikari Power Ltd now owns 2,500,000 shares of the biopharmaceutical company’s stock worth $4,250,000 after buying an additional 200,000 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its holdings in Synergy Pharmaceuticals by 7.2% during the second quarter. Schwab Charles Investment Management Inc. now owns 1,312,030 shares of the biopharmaceutical company’s stock worth $2,283,000 after buying an additional 88,386 shares in the last quarter. 38.60% of the stock is currently owned by institutional investors and hedge funds.

SGYP stock opened at $0.24 on Thursday. The stock has a market cap of $50.30 million, a P/E ratio of -0.23 and a beta of 3.02. Synergy Pharmaceuticals Inc has a 52 week low of $0.07 and a 52 week high of $2.80.

Synergy Pharmaceuticals (NASDAQ:SGYP) last announced its earnings results on Thursday, November 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.01). The business had revenue of $11.11 million for the quarter, compared to the consensus estimate of $15.65 million. As a group, analysts forecast that Synergy Pharmaceuticals Inc will post -0.54 EPS for the current year.

A number of research firms recently commented on SGYP. BTIG Research downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Friday, October 26th. Canaccord Genuity downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, October 26th. Finally, Zacks Investment Research downgraded shares of Synergy Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, October 10th. One analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $6.50.

TRADEMARK VIOLATION NOTICE: “BlackRock Inc. Has $37.91 Million Stake in Synergy Pharmaceuticals Inc (SGYP)” was reported by Fairfield Current and is the sole property of of Fairfield Current. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark laws. The original version of this news story can be accessed at https://www.fairfieldcurrent.com/news/2019/01/17/blackrock-inc-has-37-91-million-stake-in-synergy-pharmaceuticals-inc-sgyp.html.

Synergy Pharmaceuticals Company Profile

Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.

Read More: How is the LIBOR rate calculated?

Want to see what other hedge funds are holding SGYP?Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Synergy Pharmaceuticals Inc (NASDAQ:SGYP).

Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts:

  • No Related Posts

Alyeska Investment Group LP Buys 696911 Shares of Synergy Pharmaceuticals Inc (NASDAQ …

Vanguard Group Inc. boosted its stake in Synergy Pharmaceuticals by 10.4% in the 2nd quarter. Vanguard Group Inc. now owns 17,422,326 shares of the biopharmaceutical company’s stock worth $77,530,000 after purchasing an additional 1,636,563 shares during the period. State Street Corp raised …

Synergy Pharmaceuticals logoAlyeska Investment Group L.P. lifted its stake in shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP) by 42.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,355,681 shares of the biopharmaceutical company’s stock after acquiring an additional 696,911 shares during the quarter. Alyeska Investment Group L.P. owned approximately 1.05% of Synergy Pharmaceuticals worth $6,831,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Vanguard Group Inc. boosted its stake in Synergy Pharmaceuticals by 10.4% in the 2nd quarter. Vanguard Group Inc. now owns 17,422,326 shares of the biopharmaceutical company’s stock worth $77,530,000 after purchasing an additional 1,636,563 shares during the period. State Street Corp raised its holdings in shares of Synergy Pharmaceuticals by 2.4% during the 2nd quarter. State Street Corp now owns 12,933,104 shares of the biopharmaceutical company’s stock worth $57,552,000 after acquiring an additional 306,989 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Synergy Pharmaceuticals by 71.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 3,405,377 shares of the biopharmaceutical company’s stock worth $8,820,000 after acquiring an additional 1,417,177 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Synergy Pharmaceuticals by 15.3% during the 2nd quarter. Northern Trust Corp now owns 2,804,768 shares of the biopharmaceutical company’s stock worth $12,481,000 after acquiring an additional 372,683 shares in the last quarter. Finally, Pictet Asset Management Ltd. raised its holdings in shares of Synergy Pharmaceuticals by 30.8% during the 3rd quarter. Pictet Asset Management Ltd. now owns 2,611,536 shares of the biopharmaceutical company’s stock worth $7,574,000 after acquiring an additional 615,025 shares in the last quarter. Institutional investors own 60.42% of the company’s stock.

Shares of Synergy Pharmaceuticals Inc (SGYP) traded up $0.03 during mid-day trading on Wednesday, reaching $2.48. The company had a trading volume of 7,482,658 shares, compared to its average volume of 6,210,000. Synergy Pharmaceuticals Inc has a 12 month low of $1.68 and a 12 month high of $7.15. The company has a market capitalization of $611.72, a P/E ratio of -2.14 and a beta of 1.22. The company has a debt-to-equity ratio of -68.13, a quick ratio of 3.88 and a current ratio of 4.26.

Synergy Pharmaceuticals (NASDAQ:SGYP) last released its quarterly earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.06. The business had revenue of $5.01 million during the quarter, compared to analysts’ expectations of $4.53 million. During the same quarter last year, the business posted ($0.22) earnings per share. sell-side analysts predict that Synergy Pharmaceuticals Inc will post -1.04 EPS for the current fiscal year.

Several analysts recently weighed in on the company. Oppenheimer set a $6.00 price target on Synergy Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, October 10th. HC Wainwright set a $8.00 price target on Synergy Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, October 11th. BTIG Research reiterated a “buy” rating and issued a $7.00 target price on shares of Synergy Pharmaceuticals in a research note on Tuesday, November 14th. BidaskClub upgraded Synergy Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, December 22nd. Finally, Citigroup reiterated a “sell” rating and issued a $2.50 target price (down previously from $3.20) on shares of Synergy Pharmaceuticals in a research note on Wednesday, September 13th. Three investment analysts have rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company. Synergy Pharmaceuticals has an average rating of “Hold” and an average target price of $7.98.

In other news, major shareholder Paulson & Co. Inc. sold 8,750,000 shares of the firm’s stock in a transaction dated Friday, November 10th. The stock was sold at an average price of $2.82, for a total value of $24,675,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 3.80% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Alyeska Investment Group L.P. Buys 696,911 Shares of Synergy Pharmaceuticals Inc (NASDAQ:SGYP)” was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another website, it was illegally copied and reposted in violation of US & international copyright and trademark law. The original version of this article can be accessed at https://ledgergazette.com/2018/01/04/alyeska-investment-group-l-p-has-6-83-million-position-in-synergy-pharmaceuticals-inc-sgyp.html.

About Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.

Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts: